{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:59:48Z","timestamp":1769579988864,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFB142"],"award-info":[{"award-number":["2022CFB142"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104507"],"award-info":[{"award-number":["82104507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jchromb.2024.124276","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T02:11:55Z","timestamp":1724379115000},"page":"124276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS\/MS: applications to therapeutic drug monitoring and drug-drug interaction studies"],"prefix":"10.1016","volume":"1246","author":[{"given":"Ninghong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuepeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9976","key":"10.1016\/j.jchromb.2024.124276_b0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jchromb.2024.124276_b0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jchromb.2024.124276_b0015","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin. Pharmacol.-Adv. Appl."},{"key":"10.1016\/j.jchromb.2024.124276_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics","volume":"12","author":"He","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jchromb.2024.124276_b0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol. Pharm. Bull."},{"issue":"5","key":"10.1016\/j.jchromb.2024.124276_b0030","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.jchromb.2024.124276_b0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/jphp.12757","article-title":"Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling","volume":"69","author":"Boons","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124276_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.569843","article-title":"Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.jchromb.2024.124276_b0045","first-page":"899","article-title":"Invasive fungal infections in hematologic malignancies\u2013a retrospective study of 61 autopsied cases","volume":"36","author":"Kuzuyama","year":"1990","journal-title":"Gan No Rinsho"},{"issue":"3","key":"10.1016\/j.jchromb.2024.124276_b0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0924-8579(00)00159-X","article-title":"Prophylaxis and treatment of fungal infections associated with haematological malignancies","volume":"15","author":"Ascioglu","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jchromb.2024.124276_b0055","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/CMAR.S238166","article-title":"Risk prediction and prognosis of invasive fungal disease in hematological malignancies patients complicated with bloodstream infections","volume":"12","author":"Xiao","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jchromb.2024.124276_b0060","doi-asserted-by":"crossref","unstructured":"J.A. Maertens, C. Girmenia, R.J. Bruggemann, R.F. Duarte, C.C. Kibbler, P. Ljungman, Z. Racil, P. Ribaud, M.A. Slavin, O.A. Cornely, D.J. Peter, C. Cordonnier, European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia, J. Antimicrob. Chemother. 73 (12) (2018) 3221-3230, doi: 10.1093\/jac\/dky286.","DOI":"10.1093\/jac\/dky286"},{"key":"10.1016\/j.jchromb.2024.124276_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/epirev\/mxae003","article-title":"A review on the epidemiology of invasive fungal infections in Asian patients with haematological malignancies (2011\u20132021)","author":"Iyadorai","year":"2024","journal-title":"Epidemiol. Rev."},{"issue":"8","key":"10.1016\/j.jchromb.2024.124276_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jchromb.2024.124276_b0075","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/INF.0b013e31821b958c","article-title":"Antifungal azoles: old and new","volume":"30","author":"Blyth","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"1","key":"10.1016\/j.jchromb.2024.124276_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS","volume":"878","author":"Alffenaar","year":"2010","journal-title":"J. Chromatogr. B"},{"issue":"5","key":"10.1016\/j.jchromb.2024.124276_b0085","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2024.124276_b0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clinbiochem.2019.06.003","article-title":"Experience with therapeutic drug monitoring of three antifungal agents using an LC-MS\/MS method in routine clinical practice","volume":"70","author":"Yoon","year":"2019","journal-title":"Clin. Biochem."},{"issue":"8","key":"10.1016\/j.jchromb.2024.124276_b0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.jchromb.2024.124276_b0100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/00498254.2018.1473662","article-title":"The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes","volume":"49","author":"Luo","year":"2019","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.jchromb.2024.124276_b0105","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3109\/03639045.2013.838582","article-title":"Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat","volume":"40","author":"Lin","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"4","key":"10.1016\/j.jchromb.2024.124276_b0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.jchromb.2024.124276_b0115","first-page":"391","article-title":"Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization","volume":"72","author":"Scodavolpe","year":"2014","journal-title":"Ann. Biol. Clin."},{"issue":"5","key":"10.1016\/j.jchromb.2024.124276_b0120","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.jchromb.2024.124276_b0125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5694\/j.1326-5377.2007.tb01313.x","article-title":"Antifungal agents","volume":"187","author":"Chen","year":"2007","journal-title":"Med. J. Aust."},{"issue":"Suppl 7","key":"10.1016\/j.jchromb.2024.124276_b0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.jchromb.2024.124276_b0135","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1248\/bpb.b15-00330","article-title":"Preparation of antibodies and development of an enzyme-linked immunosorbent assay for the tyrosine kinase inhibitors lapatinib and nilotinib","volume":"38","author":"Saita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.jchromb.2024.124276_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030947","article-title":"Therapeutic drug monitoring in oncohematological patients: a fast and accurate HPLC-UV method for the quantification of nilotinib in human plasma and its clinical application","volume":"11","author":"Escudero-Ortiz","year":"2023","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.jchromb.2024.124276_b0145","doi-asserted-by":"crossref","first-page":"e24598","DOI":"10.1002\/jcla.24598","article-title":"Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection","volume":"36","author":"Yokoyama","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.jchromb.2024.124276_b0150","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2147\/DDDT.S301241","article-title":"Development of UPLC-MS\/MS method for studying the pharmacokinetic interaction between dasatinib and posaconazole in rats","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jchromb.2024.124276_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2012.12.028","article-title":"Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry","volume":"919\u2013920","author":"Jourdil","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2024.124276_b0160","unstructured":"Food and Drug Administration. Bioanalytical method validation guidance. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed January 11, 2022."},{"key":"10.1016\/j.jchromb.2024.124276_b0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","article-title":"UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma","volume":"166","author":"Xu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.jchromb.2024.124276_b0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/FTD.0000000000000406","article-title":"Simultaneous determination of imatinib, dasatinib, and nilotinib by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring","volume":"39","author":"Wojnicz","year":"2017","journal-title":"Ther. Drug Monit."},{"issue":"8","key":"10.1016\/j.jchromb.2024.124276_b0175","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jchromb.2024.124276_b0180","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jchromb.2024.124276_b0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.jchromb.2024.124276_b0190","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jchromb.2024.124276_b0195","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2012.02.002","article-title":"Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies","volume":"39","author":"Hoenigl","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Suppl 1","key":"10.1016\/j.jchromb.2024.124276_b0200","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"10.1016\/j.jchromb.2024.124276_b0205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","article-title":"Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation","volume":"16","author":"Van Daele","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.jchromb.2024.124276_b0210","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.jchromb.2024.124276_b0215","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","article-title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","volume":"54","author":"Dutreix","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124276_b0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2147\/IDR.S199526","article-title":"Drug-drug interaction study of imatinib and voriconazole in vitro and in vivo","volume":"12","author":"Lin","year":"2019","journal-title":"Infect. Drug Resistance"},{"issue":"8","key":"10.1016\/j.jchromb.2024.124276_b0225","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jchromb.2024.124276_b0230","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jchromb.2024.124276_b0235","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1124\/dmd.107.020255","article-title":"Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics","volume":"36","author":"Wang","year":"2008","journal-title":"Drug Metab. Dispos."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322400285X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322400285X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T05:04:55Z","timestamp":1726376695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157002322400285X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":47,"alternative-id":["S157002322400285X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124276","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS\/MS: applications to therapeutic drug monitoring and drug-drug interaction studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124276"}}